RDHL - RedHill Biopharma Ltd.

2.34
0.290   12.393%

Share volume: 60,527
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$2.05
0.29
0.14%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
15%
Profitability 15%
Dept financing 13%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
20.00%
1 Month
-22.52%
3 Months
-60.07%
6 Months
-71.00%
1 Year
369.88%
2 Year
-20.68%
Key data
Stock price
$2.34
P/E Ratio 
0.00
DAY RANGE
$2.12 - $2.48
EPS 
-$1.53
52 WEEK RANGE
$0.28 - $12.50
52 WEEK CHANGE
$385.98
MARKET CAP 
10.835 M
YIELD 
N/A
SHARES OUTSTANDING 
1.275 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
1.02
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$38,008
AVERAGE 30 VOLUME 
$117,727
Company detail
CEO: Dror Ben-Asher
Region: US
Website: redhillbio.com
Employees: 210
IPO year: 2013
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

RedHill Biopharma Ltd. primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections.

Recent news
loading